Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo

Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo

Abstract Background Acute leukemias represent deadly malignancies that require better treatment. As a challenge, treatment is counteracted by a microenvironment protecting dormant leukemia stem cells. Methods To identify responsible surface proteins, we performed deep proteome profiling on minute nu...

Full description

Bibliographic Details
Main Authors: Ehsan Bahrami, Jan Philipp Schmid, Vindi Jurinovic, Martin Becker, Anna-Katharina Wirth, Romina Ludwig, Sophie Kreissig, Tania Vanessa Duque Angel, Diana Amend, Katharina Hunt, Rupert Öllinger, Roland Rad, Joris Maximilian Frenz, Maria Solovey, Frank Ziemann, Matthias Mann, Binje Vick, Christian Wichmann, Tobias Herold, Ashok Kumar Jayavelu, Irmela Jeremias
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Molecular Cancer
Subjects:
CRISPR-Cas9 in vivo screen
Proteomics
ADAM10
PDX
Acute leukemia
Leukemia stem cells
Online Access:https://doi.org/10.1186/s12943-023-01803-0

Internet

https://doi.org/10.1186/s12943-023-01803-0

Similar Items